Expand CBAY Menu
CBAY MENU

CBAY Latest Press Releases

-- March 22, 2024 --

Gilead Sciences Announces Completion of Acquisition of CymaBay Business Wire 9:18 AM

-- March 4, 2024 --

CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis Globe Newswire 8:00 AM

-- February 29, 2024 --

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI PRNewswire 6:30 PM

-- February 28, 2024 --

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update Globe Newswire 4:45 PM

-- February 24, 2024 --

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE Globe Newswire 10:10 AM

-- February 21, 2024 --

The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis PRNewswire 5:43 PM

-- February 20, 2024 --

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- February 17, 2024 --

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, ZFOX, CBAY, WISH Globe Newswire 12:18 PM

-- February 16, 2024 --

CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY Business Wire 1:58 PM

-- February 12, 2024 --

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FANG, CBAY, WISH Globe Newswire 5:45 PM
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm PRNewswire 1:43 PM
INVESTIGATION ALERT: Halper Sadeh LLC Investigates FANG, WISH, CBAY PRNewswire 12:30 PM
Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead PRNewswire 11:45 AM
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders Business Wire 9:35 AM
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis PRNewswire 8:45 AM
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics Business Wire 8:30 AM

-- January 31, 2024 --

CymaBay Therapeutics to Participate in Upcoming Investment Conferences Globe Newswire 8:00 AM

-- January 16, 2024 --

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:28 PM

-- January 3, 2024 --

New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar PRNewswire 8:00 AM

-- January 2, 2024 --

CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024 Globe Newswire 8:00 AM

-- December 18, 2023 --

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- December 15, 2023 --

CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis PRNewswire 8:00 AM